Pegfilgrastim biosimilar - Pfizer
Alternative Names: HSP-130; NYVEPRIA; Pegfilgrastim-apgf; Pegylated filgrastim - Hospira; PF-06881894Latest Information Update: 09 Dec 2025
At a glance
- Originator Hospira
- Developer Hospira; Pfizer
- Class Antineoplastics; Chemoprotectants; Granulocyte colony-stimulating factors; Polyethylene glycols; Radioprotectives; Recombinant proteins
- Mechanism of Action Granulocyte colony stimulating factor replacements; Granulocyte colony-stimulating factor receptor agonists
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Neutropenia
Most Recent Events
- 09 Dec 2025 Pegfilgrastim biosimilar is registered for Neutropenia (Chemotherapy-induced, Prevention) in USA and European Union
- 02 Nov 2023 Launched for Neutropenia (Prevention, Chemotherapy-induced) in Hungary (SC)
- 27 Sep 2022 Launched for Neutropenia (Chemotherapy-induced, Prevention) in Canada (SC)